share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/07/27 00:08

Moomoo AI 已提取核心信息

Bristol-Myers Squibb reported Q2 2024 revenues of $12.2 billion, up 9% year-over-year, driven by strong performance in its Growth Portfolio and Eliquis. Net earnings were $1.68 billion with diluted EPS of $0.83. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.6 billion, while the Legacy Portfolio grew 2% to $6.6 billion.The company completed several strategic acquisitions in 2024, including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, strengthening its pipeline across key therapeutic areas. BMS also entered into a collaboration with SystImmune for co-development of BL-B01D1. To fund these acquisitions, the company issued $13 billion in senior unsecured notes during Q1 2024.Looking ahead, BMS continues to execute on its $1.5 billion cost savings initiative by end of 2025, focusing resources on R&D programs with the highest potential returns. The company received multiple regulatory approvals including Breyanzi for additional indications and Krazati for colorectal cancer. Operating cash flow remained strong at $5.2 billion for the first half of 2024, supporting continued investment in innovation and growth.
Bristol-Myers Squibb reported Q2 2024 revenues of $12.2 billion, up 9% year-over-year, driven by strong performance in its Growth Portfolio and Eliquis. Net earnings were $1.68 billion with diluted EPS of $0.83. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.6 billion, while the Legacy Portfolio grew 2% to $6.6 billion.The company completed several strategic acquisitions in 2024, including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, strengthening its pipeline across key therapeutic areas. BMS also entered into a collaboration with SystImmune for co-development of BL-B01D1. To fund these acquisitions, the company issued $13 billion in senior unsecured notes during Q1 2024.Looking ahead, BMS continues to execute on its $1.5 billion cost savings initiative by end of 2025, focusing resources on R&D programs with the highest potential returns. The company received multiple regulatory approvals including Breyanzi for additional indications and Krazati for colorectal cancer. Operating cash flow remained strong at $5.2 billion for the first half of 2024, supporting continued investment in innovation and growth.
施贵宝报告称2024年第二季度营业收入为122亿，同比增长9%，主要受到其增长组合和Eliquis强劲表现的驱动。净收益为16.8亿，摊薄后每股收益为0.83美元。增长组合，包括Opdivo、Orencia和Yervoy，营业收入增加18%至56亿，而传统组合增长2%至66亿。公司在2024年完成了几项战略收购，包括Karuna Therapeutics、RayzeBio和Mirati Therapeutics，加强了其在关键治疗领域的产品线。施贵宝还与SystImmune达成合作，共同开发BL-B01D1。为了资助这些收购，公司在2024年第一季度发行了130亿的高级无担保票据。展望未来，施贵宝继续执行其到2025年底节省15亿成本的计划，集中资源于回报潜力最高的研发项目。公司获得了多个监管批准，包括Breyanzi的额外适应症和Krazati用于结直肠癌。2024年上半年的经营现金流保持强劲，达到52亿，支持持续的创新与增长投资。
施贵宝报告称2024年第二季度营业收入为122亿，同比增长9%，主要受到其增长组合和Eliquis强劲表现的驱动。净收益为16.8亿，摊薄后每股收益为0.83美元。增长组合，包括Opdivo、Orencia和Yervoy，营业收入增加18%至56亿，而传统组合增长2%至66亿。公司在2024年完成了几项战略收购，包括Karuna Therapeutics、RayzeBio和Mirati Therapeutics，加强了其在关键治疗领域的产品线。施贵宝还与SystImmune达成合作，共同开发BL-B01D1。为了资助这些收购，公司在2024年第一季度发行了130亿的高级无担保票据。展望未来，施贵宝继续执行其到2025年底节省15亿成本的计划，集中资源于回报潜力最高的研发项目。公司获得了多个监管批准，包括Breyanzi的额外适应症和Krazati用于结直肠癌。2024年上半年的经营现金流保持强劲，达到52亿，支持持续的创新与增长投资。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间